March 26, 2013 - The court granted the defendants' motions to dismiss and ordered the case closed.
May 25, 2012 - The defendants filed motions to dismiss.

April 27, 2012 - The lead plaintiff filed an amended consolidated complaint.

March 22, 2012 - Lead plaintiff and lead counsel were appointed and all cases were consolidated.

November 10, 2011 - An investor in shares of Human Genome Sciences (NASDAQ: HGSI) filed a lawsuit in the U.S. District Court for the District of Maryland against Human Genome Sciences over alleged Violations of Federal Securities Laws.

Benlysta(R) (belimumab) ( Benlysta ) is Human Genome Sciences' potential new drug for the treatment of Systemic Lupus Erythematosus, a chronic, life-threatening autoimmune disease. According to the complaint the plaintiff alleges on behalf of those purchasing HGSI common stock between July 20, 2009 and November 11, 2010, including all persons who acquired HGSI common stock in the July 28, 2009 public offering and in its December 2, 2009 public offering that Human Genome Sciences violated the violations of the Securities Exchange Act of 1934. Specifically the complaint alleges that that between July 20, 2009 and November 11, 2010 Human Genome Sciences issued allegedly false and misleading statements concerning Benlysta and that defendants failed to disclose that Benlysta was allegedly associated with suicide in clinical drug trials conducted by Human Genome Sciences.

Human Genome Sciences’ annual Revenue dropped from $275.75million in ’09 to $157.35million in 2010 and its Net Income of $5.66million from 2009 to a Net Loss of $233.23million in 2010. For the first three quarters Human Genome Sciences reported a combined nine months Revenue of only $85.45million with a nine months Net Loss of $300.09million.

Despite significant finance losses, shares of Human Genome Sciences (NASDAQ: HGSI) rose from $0.71 per share in March ’09 to as high as $32.86 per share in April 2010.

Then on November 12, 2010 the U.S. Food and Drug Administration (“FDA”) posted its analysis of Benlysta on the Internet. The plaintiff claims that investors then learned for the first time of the association between Benlysta and suicide in clinical trials of the drug and the stock price dropped significantly. In fact, shares of Human Genome Sciences (NASDAQ: HGSI) fell from over $30 in September to $23.60 on November 12, 2010.

During the first months of 2011 NASDAQ: HGSI shares increased to almost $30 per share but have since dropped to under $10 per share.